Shanghai ZJ Bio-Tech CoSHSE:688317 -3.76%69 EV-to-FCF is 9.44 as of Jun. 27, 2026, which is 16% below its 10-year median of 11.19. GuruFocus rates SHSE:688317 with a GF Score™ of 69/100 and a GF Value™ of ¥9.93 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 421 Medical Devices & Instruments companies, Shanghai ZJ Bio-Tech Co ranks better than 74.11% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Shanghai ZJ Bio-Tech Co's Enterprise Value is ¥370.1 Mil.
Shanghai ZJ Bio-Tech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ¥39.2 Mil. Therefore, Shanghai ZJ Bio-Tech Co's EV-to-FCF for today is 9.44.
The historical rank and industry rank for Shanghai ZJ Bio-Tech Co's EV-to-FCF or its related term are showing as below:
SHSE:688317'
s EV-to-FCF Range Over the Past 10 Years
Min: -284.58 Med: 11.19 Max: 80.18
Current: 9.44
During the past 13 years, the highest EV-to-FCF of Shanghai ZJ Bio-Tech Co was 80.18. The lowest was -284.58. And the median was 11.19.
SHSE:688317's EV-to-FCF is ranked better than 74.11% of 421
companies
in the Medical Devices & Instruments industry
Industry Median: 22.82
vs SHSE:688317: 9.44
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai ZJ Bio-Tech Co (SHSE:688317) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai ZJ Bio-Tech Co's PE Ratio (TTM) for today is calculated as:
Shanghai ZJ Bio-Tech Co's share price for today is ¥15.09.
Shanghai ZJ Bio-Tech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.260.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688317 vs ABT, SYK, MDT: EV-to-FCF Comparison
For the Medical Devices subindustry, Shanghai ZJ Bio-Tech Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai ZJ Bio-Tech Co EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shanghai ZJ Bio-Tech Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Shanghai ZJ Bio-Tech Co's EV-to-FCF falls into.
Shanghai ZJ Bio-Tech Co's current Enterprise Value is ¥370.1 Mil.
Shanghai ZJ Bio-Tech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥39.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai ZJ Bio-Tech Co (SHSE:688317) has a EV-to-FCF of 9.44 as of Jun. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shanghai ZJ Bio-Tech Co and its competitors. This is 16% below median its historical median of 11.19. According to the industry distribution chart, Shanghai ZJ Bio-Tech Co ranks #109 out of 421 companies in the Medical Devices & Instruments industry, placing it in the top 25.9%.
Is Shanghai ZJ Bio-Tech Co's EV-to-FCF too high?
Shanghai ZJ Bio-Tech Co's current EV-to-FCF of 9.44 is 16% below median its 10-year median of 11.19. The Medical Devices & Instruments industry median EV-to-FCF is 22.82. Shanghai ZJ Bio-Tech Co's value of 9.44 is 58.6% below this industry median. Based on the distribution chart, Shanghai ZJ Bio-Tech Co ranks #109 out of 421 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Shanghai ZJ Bio-Tech Co has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai ZJ Bio-Tech Co's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai ZJ Bio-Tech Co ranks #109 out of 421 companies for EV-to-FCF. This puts Shanghai ZJ Bio-Tech Co in the upper half of its industry. The industry median EV-to-FCF is 22.82. Shanghai ZJ Bio-Tech Co's value of 9.44 is 58.6% below this benchmark. While the company's 10-year median is 11.19 vs. the industry median of 22.82, Shanghai ZJ Bio-Tech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.82, based on 421 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai ZJ Bio-Tech Co's current EV-to-FCF of 9.44 is 58.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shanghai ZJ Bio-Tech Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai ZJ Bio-Tech Co's current EV-to-FCF is 9.44, which is 16% below median its own 10-year median of 11.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai ZJ Bio-Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co (SHSE:688317) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥9.93, compared to a current price of ¥15.09 — trading 52% above its estimated fair value. The current EV-to-FCF is 9.44, which is 16% below median its 10-year median of 11.19 and 58.6% below the Medical Devices & Instruments industry median of 22.82. Shanghai ZJ Bio-Tech Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Shanghai ZJ Bio-Tech Co (SHSE:688317), the current EV-to-FCF is 9.44 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai ZJ Bio-Tech Co (SHSE:688317) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co stock appears to be overvalued.
The current stock price of ¥15.09 is trading 52% above its estimated GF Value™ of ¥9.93.
GuruFocus considers Shanghai ZJ Bio-Tech Co to be Significantly Overvalued.
Key valuation signals for SHSE:688317:
EV-to-FCF: 9.44 (16% below median its 10-year median of 11.19)
GF Value™: ¥9.93 vs. price of ¥15.09 (52% above fair value)
Industry Position: 58.6% below the Medical Devices & Instruments median (#109 of 421)
No single metric tells the full story. See the SHSE:688317 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai ZJ Bio-Tech Co Ltd is engaged in research and development, production and sales of genetic diagnostic reagents and instruments and equipment. The rapid real-time fluorescent PCR diagnostic test reagents developed by the company are mainly used in clinical medicine, public health emergencies, entry-exit inspection and quarantine, food inspection, animal husbandry, aquaculture and other fields.
69GF Score
Get the complete analysis for SHSE:688317
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688317 has been successfully added to your 
